Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

Intellia Therapeutics  / Equity Bottom-Up

Summary: We consider <a href="https://www.smartkarma.com/entities/23650" target="_blank" data-smartkarma-citation="entities:23650:1">Intellia Therapeutics Inc (NTLA US)</a> stock undervalued at current price level. Out first price target is US$32 (sum-of-the parts, risk-adjusted NPV method), which could mean more than 100% upside (2-3 years time-frame).CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has been in the news recently after being called the discovery of the century. CRISPR is a part of the acquired immune system that protects bacteria and other organisms against attacks by…

 Summary: We consider Intellia Therapeutics Inc (NTLA US) stock undervalued at current price level. Out first price target is US$32 (sum-of-the parts, risk-adjusted NPV method), which could mean more than 100% upside (2-3 years time-frame).CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has been in the news recently after being called the discovery of the century. CRISPR is a part of the acquired immune system that protects bacteria and other organisms against attacks by…

CRISPR Gene Editing Technology Could Change the World, Part I: Intellia Therapeutics